Human antibodies interacting with HIV gp41

Details Human antibodies interacting with HIV gp41 Human antibodies interacting with HIV gp41

2005-05-31

2010-06-29

Peng, Bo (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S147100, C424S130100, C436S512000, C530S387100

Reexamination Certificate

active

07744887

ABSTRACT:
Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which encode relevant portions of these antibodies, as well as the purified forms of the expressed antibodies or relevant antibody fragments, such as VHand VLchains. The antibody compositions disclosed within this specification may provide for a therapeutic treatment against HIV infection by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV infection. These antibodies will also be useful in assays to identify HIV antiviral compounds as well as allowing for the identification of candidate HIV vaccines, such as HIV peptide vaccines.

REFERENCES:
patent: 5444044 (1995-08-01), Jiang et al.
patent: 5459060 (1995-10-01), Cotropia et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 5731189 (1998-03-01), Zolla-Pazner et al.
patent: 5753503 (1998-05-01), Katinger et al.
patent: 5777074 (1998-07-01), Cotropia et al.
patent: 5831034 (1998-11-01), Katinger et al.
patent: 6008044 (1999-12-01), Cotropia et al.
patent: 6083504 (2000-07-01), Cotropia et al.
patent: 6150088 (2000-11-01), Chan et al.
patent: 6506554 (2003-01-01), Chan et al.
patent: 6596497 (2003-07-01), Jiang et al.
patent: 6605427 (2003-08-01), Wild et al.
patent: 6747126 (2004-06-01), Eckert et al.
patent: 6818740 (2004-11-01), Eckert et al.
patent: 6841657 (2005-01-01), Eckert et al.
patent: 7053179 (2006-05-01), Root et al.
patent: 7402396 (2008-07-01), Chan et al.
patent: 2001/0047080 (2001-11-01), Root et al.
patent: 2003/0059862 (2003-03-01), Ruben
patent: 2003/0118985 (2003-06-01), Hunt et al.
patent: 0 335 134 (1989-03-01), None
patent: WO 89/04370 (1989-05-01), None
patent: WO 90/09805 (1990-09-01), None
patent: WO 94/28920 (1994-12-01), None
patent: WO 98/50431 (1998-11-01), None
patent: WO 00/40616 (2000-07-01), None
patent: WO 01/44286 (2001-06-01), None
patent: WO 03/052122 (2003-06-01), None
patent: WO 2005/118886 (2005-12-01), None
Keller et al. :Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. Oct. 2000;13(4):602-14.
Trkola, et al. “Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.” Nat Med, 2005, 11(6):615-22.
Lemckert A. et al “Challenges in the search for an HIV vaccine”. Eur J Epidemiol. 2004;19(6):513-6.
Tamura et al “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only”. J Immunol. Feb. 1, 2000;164(3):1432-41.
Kashmiri et al. “SDR grafting—a new approach to antibody humanization” Methods. May 2005;36(1):25-34.
Jiang, Shibo, et al, Journal of Virological Methods, “A screening assay for antiviral compounds to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody”, vol. 80, pp. 85-96, 1999.
Louis, John M., et al., The Journal of Biological Chemistry, “Design and Properties of Nccg-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity”, vol. 276, No. 31, pp. 29485-29489, 2001.
Louis, John M., et al., The Journal of Biological Chemistry, “Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion”, vol. 278, No. 22, pp. 20278-20285, 2003.
Caffrey, Michael, et al., EMBO J., “Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41”, vol. 17, No. 16, pp. 4572-4584, 1998.
Chan, David C., et al., Cell, “Core structure of gp41 from the HIV envelope glycoprotein”, vol. 89, pp. 263-273, 1997.
Chan, Davide C., et al., Proc. Natl. Acad. Sci, “Evidence that a prominent cavity in the coiled coil of HIV type I gp41 is an attractive drug target”, vol. 95, pp. 15613-15617, 1998.
Chan, David C., et al., Cell, “HIV entry and its inhibition”, vol. 93, pp. 681-684, 1998.
Dong, Xiao-Nan, et al., Immunology Letters, “N- and C-domains of HIV-1 gp41: Mutation, structure and functions”, vol. 75, pp. 215-220, 2001.
Earl, Patricia L., et al., Journal of Virology, “Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein”, vol. 71, No. 4, pp. 2674-2684, 1997.
Eckert, Debra M., et al., Cell, “Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket”, vol. 99, pp. 103-115, 1999.
Eckert, Debra M., et al., Annu. Rev. Biochem., “Mechanisms of viral membrane fusion and its inhibition”, vol. 70, pp. 777-810, 2001.
Eckhart, Leopold, et al., Journal of General Virology, “Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus”, vol. 77, pp. 2001-2008, 1996.
Ferrer, Marc, et al., Nature Structural Biology, “Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements”, vol. 6, No. 10, pp. 953-960, 1999.
Jiang, Shibo, et al, Journal of Virology, “A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein”, vol. 72, No. 12, pp. 10213-10217, 1998.
Jiang, Shibo, et al., Biochemical and Biophysical Research Communications, “Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41”, vol. 269, pp. 641-646, 2000.
Judice, J. Kevin, et al., Proc. Natl. Acad. Sci., “Inhibition of HIV type 1 infectivity by constrained-helical peptides: Implications for the viral fusion mechanism”, vol. 94, pp. 13426-13430, 1997.
Malashkevic, Vladimir N., et al.,Proc. Natl. Acad. Sci., “Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides”, vol. 95, pp. 9134-9139, 1998.
Vaughn, Tristan J., et al., Nature Biotechnology, “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library”, vol. 14, pp. 309-314, 1996.
Weissenhorn, Winfried, et al., Proc. Natl. Acad. Sci. USA, “Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed inEscherichia coli”, vol. 94, pp. 6065-6069, 1997.
Weissenhorn, Winfried, et al., Nature, “Atomic structure of the ectodomain from HIV-1 gp41”, vol. 387, pp. 426-429, 1997.
Wild, Carl T., et al., Proc. Natl. Acad. Sci. USA, “Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection”, vol. 97, pp. 9770-9774, 1994.
Zwick, Michael B., et al., Journal of Virology, “Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41”, vol. 75, No. 22, pp. 10892-10905 2001.
Eckert et al., “Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region”, Proceedings Nat'l Academy of Sciences, vol. 98, No. 20, pp. 11187-11192 (2001).
Golding et al., “Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates”, Journal of Virology, vol. 76, No. 13, pp. 6780-6790 (2002).
Miller et al., “A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp4 I epitope”, Proceedings Nat'l Academy of Sci

Affiliated with

Also associated with

Rating

Human antibodies interacting with HIV gp41 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human antibodies interacting with HIV gp41, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antibodies interacting with HIV gp41 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4230268